ALB and neoplasm: As showed in our recent study that pharmacokinetics of 15d-PGJ2 is controlled by its albumin binding and tumor vasculature [4], in order to apply 15d-PGJ2 for therapeutic purpose it would be highly interesting to employ a tumor drug delivery approach to improve its pharmacokinetics and to achieve tumor-specific effects.